Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Ligand Pharma ( (LGND) ).
On April 27, 2026, Ligand Pharmaceuticals entered into a merger agreement under which its wholly owned subsidiary Flex Merger Sub will merge with XOMA Royalty’s newly formed Nevada entity, XOMA Royalty Holdings Corporation, which will survive as a wholly owned subsidiary of Ligand following a holding company reorganization. On May 16, 2026, the parties amended the agreement to add the new holding company as a formal party, advancing Ligand’s planned acquisition of XOMA Royalty and setting the stage for a shareholder vote that could reshape Ligand’s royalty portfolio and integration efforts in the biotech royalty market.
The transaction remains subject to several conditions, including regulatory approvals and approval by XOMA Royalty stockholders, and the companies highlighted numerous risks that could delay or prevent closing, such as competing offers, integration challenges and potential litigation. Investors are directed to review XOMA Royalty’s forthcoming proxy materials and existing SEC filings, which detail uncertainties around realizing anticipated benefits, dependence on partners for royalties and clinical outcomes, and broader market and regulatory risks that could affect both companies’ future performance.
The most recent analyst rating on (LGND) stock is a Buy with a $263.00 price target. To see the full list of analyst forecasts on Ligand Pharma stock, see the LGND Stock Forecast page.
Spark’s Take on LGND Stock
According to Spark, TipRanks’ AI Analyst, LGND is a Outperform.
The score is driven primarily by strong financial performance (high TTM profitability and cash generation) and a constructive earnings outlook/catalyst set highlighted on the call (guidance and XOMA accretion). Technicals are neutral overall, while valuation is a notable drag due to the negative P/E and lack of dividend yield data.
To see Spark’s full report on LGND stock, click here.
More about Ligand Pharma
Ligand Pharmaceuticals is a biopharmaceutical company that operates through a portfolio of drug royalties, partnered programs and related assets, focusing on developing and acquiring therapies that generate recurring revenue streams. XOMA Royalty Corporation similarly concentrates on royalty interests linked to commercialized and pipeline pharmaceutical products, positioning both firms within the specialty and royalty-based biotech segment.
Average Trading Volume: 226,291
Technical Sentiment Signal: Buy
Current Market Cap: $4.27B
For an in-depth examination of LGND stock, go to TipRanks’ Overview page.